ESCRS - Results for add-on lens ;
ESCRS - Results for add-on lens ;

Results for add-on lens

Sulcus-fixated lens for relieving symptoms of dysphotopsia

Results for add-on lens
Roibeard O’hEineachain
Roibeard O’hEineachain
Published: Saturday, April 1, 2017
Henrik Bom Olesen MD
Implantation of a novel add-on sulcus-fixated intraocular lens (IOL), the Sulcoflex® (Rayner), appears to be highly effective in relieving symptoms of dysphotopsia and correcting residual ametropia in pseudophakic patients, according to the findings of a retrospective study presented at the XXXIV Congress of the ESCRS in Copenhagen, Denmark. The study reviewed the outcomes of implantation of the Sulcoflex add-on IOL in 50 eyes of 39 pseudophakic refractive lens exchange (RLE) patients, who underwent the procedures at clinics in Denmark, Norway and Sweden from September 2014 to February 2016, said Henrik Bom Olesen MD, Copenhagen, Denmark. The main indications for the implantation of the Sulcoflex lens were pseudophakic negative dysphotopsia, in 20 eyes of 15 patients, and residual ametropia following RLE in 42 eyes not suitable for laser vision correction, with some overlap between the two groups, Dr Olesen explained. Following implantation of the Sulcoflex lens, 17 (85%) of the eyes with negative dysphotopsia had a complete resolution of their symptoms following implantation of the lens, while two eyes (10%) had a partial resolution, and in one patient the treatment had no effect. Among eyes with residual ametropia, more than 80% of the eyes were within 0.25D of the targeted refraction calculated on Rayner’s website. However, four eyes (8%) subsequently needed laser vision correction, and one of nine toric versions of IOL implanted required repositioning.
Pseudophakic dysphotopsia is an optical phenomenon that patients experience as a crescent-shaped shadow in the temporal peripheral visual field
Dr Olesen noted that pseudophakic dysphotopsia is an optical phenomenon that patients experience as a crescent-shaped shadow in the temporal peripheral visual field. It is mostly transient, but can be persistent and bothersome in up to 1% of pseudophakic eyes. One theory regarding its cause is that it results from a splitting of oblique rays of light at a gap between the optic’s edge and the capsulorhexis edge. That is supported by the observation that such a gap is almost invariably present in eyes with the condition. Several techniques have been shown to be effective in treating or preventing the condition. They include placing the primary IOL in the sulcus, positioning the optic in front of the anterior capsule, known as optic capture, and the use of specially designed IOLs with capsule capturing optic edges. He explained that he and his associates chose the Sulcoflex option in these patients because it affords the twofold option of correcting both residual ametropia as well as negative dysphotopsia in eyes where it occurs. Henrik Bom Olesen: 
henrik.bomolesen@memira.dk
Tags: lens
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;